<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LASTACAFT- alcaftadine solution/ drops </strong><br>Allergan, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LASTACAFT<span class="Sup">®</span> safely and effectively. See full prescribing information for LASTACAFT<span class="Sup">®</span>.<br><br>LASTACAFT<span class="Sup">®</span> (alcaftadine ophthalmic solution)<br>For Topical Ophthalmic Use<br>Initial U.S. Approval: 2010
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><ul class="Disc"><li>Contraindications, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#s4">4</a>) 12/2014
</li></ul></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">LASTACAFT<span class="Sup">®</span> is an H<span class="Sub">1</span> histamine receptor antagonist indicated for the prevention of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>. (<a href="#s1">1</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Instill one drop in each eye once daily. (<a href="#s2">2</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Ophthalmic solution containing alcaftadine, 0.25% (2.5 mg/mL) (<a href="#s3">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>. (<a href="#s4">4</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>To minimize the risk of eye injury and contamination, do not touch dropper tip to eyelids and surrounding areas, or any other surface. Keep bottle tightly closed when not in use. (<a href="#s6">5.1</a>)
</li>
<li>
                              LASTACAFT<span class="Sup">®</span> should not be used to treat contact lens-related irritation. (<a href="#s7">5.2</a>)
</li>
<li>Remove contact lenses prior to instillation of LASTACAFT<span class="Sup">®</span>. (<a href="#s7">5.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common ocular adverse reactions, occurring in less than 4% of eyes treated with LASTACAFT<span class="Sup">®</span>, were <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, burning and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> on instillation, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">eye redness</span>, and <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye pruritus</span>. (<a href="#s10">6.1</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or
</span><span class="Bold">www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Potential for Eye Injury and Contamination
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Contact Lens Use
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Non-ocular Adverse Reactions 
</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">LASTACAFT<span class="Sup">®</span> is an H<span class="Sub">1</span> histamine receptor antagonist indicated for the prevention of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Instill one drop in each eye once daily. If more than 1 topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Topical ophthalmic solution containing alcaftadine, 0.25% (2.5 mg/mL).
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>LASTACAFT<span class="Sup">®</span> is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component in the product.
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Potential for Eye Injury and Contamination
</h2>
<p class="First">To minimize eye injury and contamination of the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Contact Lens Use
</h2>
<p class="First">Patients should be advised not to wear a contact lens if their eye is red. 
 </p>
<p>LASTACAFT<span class="Sup">®</span> should not be used to treat contact lens-related irritation.
</p>
<p>LASTACAFT<span class="Sup">®</span> should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of LASTACAFT<span class="Sup">®</span>. The preservative in LASTACAFT<span class="Sup">®</span>, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of LASTACAFT<span class="Sup">®</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s9"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience
</h2>
<p class="First">The most frequent ocular adverse reactions, occurring in less than 4% of eyes treated with LASTACAFT<span class="Sup">®</span>, were <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, burning and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> upon instillation, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">eye redness</span> and <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye pruritus</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e10"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Non-ocular Adverse Reactions 
</h2>
<p class="First">The most frequent non-ocular adverse reactions, occurring in less than 3% of subjects with eyes treated with LASTACAFT<span class="Sup">®</span>, were <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Some of these events were similar to the underlying disease being studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience
</h2>
<p class="First">The following adverse reactions have been identified during postmarketing use of LASTACAFT<span class="Sup">®</span> in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions include <span class="product-label-link" type="condition" conceptid="4080696" conceptname="Discharge from eye">eye discharge</span>, <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">eye swelling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of eyelid, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation increased</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s12"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s13"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<p class="First">Pregnancy Category B. Reproduction studies performed in rats and rabbits revealed no evidence of impaired female reproduction or harm to the fetus due to alcaftadine. Oral doses in rats and rabbits of 20 and 80 mg/kg/day, respectively, produced plasma exposure levels approximately 200 and 9000 times the plasma exposure at the recommended human ocular dose. There are however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s14"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when LASTACAFT<span class="Sup">®</span> is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s15"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 2 years have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s16"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness were observed between elderly and younger subjects.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s17"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">LASTACAFT<span class="Sup">®</span> is a sterile, topically administered H<span class="Sub">1</span> receptor antagonist containing alcaftadine for ophthalmic use.
</p>
<p>Alcaftadine is a white to yellow powder with an empirical formula of C<span class="Sub">19</span>H<span class="Sub">21</span>N<span class="Sub">3</span>O and a molecular weight of 307.39.
</p>
<p><span class="Bold">Contains:</span></p>
<p><span class="Bold">Active:</span> alcaftadine 0.25% (2.5 mg/mL)</p>
<p><span class="Bold">Inactives:</span> benzalkonium chloride 0.005% as a preservative; edetate disodium; sodium phosphate, monobasic; purified water; sodium chloride; sodium hydroxide and/or hydrochloric acid (to adjust pH)
</p>
<p><span class="Bold">Chemical Name:</span> 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5<span class="Italics">H</span>-imidazo[2,1-b] [3] benzazepine-3-carboxaldehyde
</p>
<p><span class="Bold">Structural Formula:</span></p>
<p><a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=17d37e8d-7825-424b-b6ca-0a85d0bf4694&amp;name=structuralformula.jpg"></p>
<p>The drug product has a pH of approximately 7 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 290 mOsm/kg.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s18"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s19"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Alcaftadine is an H<span class="Sub">1</span> histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s20"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-9.2.1"></a><p></p>
<p class="First"><span class="Italics">Absorption</span></p>
<p>Following bilateral topical ocular administration of alcaftadine ophthalmic solution, 0.25%, the mean plasma C<span class="Sub">max</span> of alcaftadine was approximately 60 pg/mL and the median T<span class="Sub">max</span> occurred at 15 minutes. Plasma concentrations of alcaftadine were below the lower limit of quantification (10 pg/mL) by 3 hours after dosing. The mean C<span class="Sub">max</span> of the active carboxylic acid metabolite was approximately 3 ng/mL and occurred at 1 hour after dosing. Plasma concentrations of the carboxylic acid metabolite were below the lower limit of quantification (100 pg/mL) by 12 hours after dosing. There was no indication of systemic accumulation or changes in plasma exposure of alcaftadine or the active metabolite following daily topical ocular administration.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-9.2.2"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>The protein binding of alcaftadine and the active metabolite are 39.2% and 62.7%, respectively.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-9.2.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>The metabolism of alcaftadine is mediated by non-CYP450 cytosolic enzymes to the active carboxylic acid metabolite.  In vitro studies showed that neither alcaftadine nor the carboxylic acid metabolite substantially inhibited reactions catalyzed by major CYP450 enzymes.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-9.2.4"></a><p></p>
<p class="First"><span class="Italics">Excretion</span></p>
<p>The elimination half-life of the carboxylic acid metabolite is approximately 2 hours following topical ocular administration. Based on data following oral administration of alcaftadine, the carboxylic acid metabolite is primarily eliminated unchanged in the urine.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s25"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s26"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Alcaftadine was not mutagenic or genotoxic in the Ames test, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay or the mouse micronucleus assay.
</p>
<p>Alcaftadine was found to have no effect on fertility of male and female rats at oral doses up to 20 mg/kg/day (approximately 200 times the plasma exposure at the recommended human ocular dose).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s27"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">Clinical efficacy was evaluated in conjunctival allergen challenge (CAC) studies. <br>LASTACAFT<span class="Sup">®</span> was more effective than its vehicle in preventing <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span> in patients with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span> induced by an ocular allergen challenge, both at 3 minutes post-dosing and at 16 hours post-dosing of LASTACAFT<span class="Sup">®</span>.
</p>
<p>The safety of LASTACAFT<span class="Sup">®</span> was evaluated in a randomized clinical study of 909 subjects over a period of 6 weeks.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s28"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">
                     LASTACAFT<span class="Sup">®</span> (alcaftadine ophthalmic solution) 0.25% is supplied in an opaque, white low-density polyethylene bottle with a white polystyrene cap. 
</p>
<p>3 mL fill in 5 mL bottle        NDC 0023-4290-03
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="e28"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store at 15°-25°C (59°-77°F).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s29"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Potential for Eye Injury and <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip</span></p>
<p>To minimize eye injury and contamination of the dropper tip and solution, patients should be advised to not touch the eyelids or surrounding areas with the dropper tip, as this may contaminate the contents.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-13.2"></a><p></p>
<p class="First"><span class="Bold">Concomitant Use with other Ophthalmic Products or Contact Lenses</span></p>
<p>If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.
</p>
<p>Patients should be advised not to wear a contact lens if their eye is red. Patients should be advised that LASTACAFT<span class="Sup">®</span> should not be used to treat contact lens-related irritation. Patients should also be advised to remove contact lenses prior to instillation of LASTACAFT<span class="Sup">®</span>. The preservative in LASTACAFT<span class="Sup">®</span>, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of LASTACAFT<span class="Sup">®</span>.
</p>
<p><br>© 2015 Allergan, Inc. All rights reserved. <br>® marks owned by Allergan, Inc.<br>Patented. See: www.allergan.com/products/patent_notices <br>Made in the U.S.A.
</p>
<p><a name="f02"></a><img alt="Allergan Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=17d37e8d-7825-424b-b6ca-0a85d0bf4694&amp;name=allerganlogo.jpg"></p>
<p>72468US13
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s33"></a><a name="section-14"></a><p></p>
<p class="First">NDC 0023-4290-03<br><span class="Bold">LASTACAFT<span class="Sup">®</span></span><br>(alcaftadine ophthalmic<br>solution) 0.25%<br><span class="Bold">3 mL</span> Sterile<br><span class="Bold">ALLERGAN</span></p>
<div class="Figure">
<a name="f03"></a><img alt="PDP Carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=17d37e8d-7825-424b-b6ca-0a85d0bf4694&amp;name=carton.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LASTACAFT 		
					</strong><br><span class="contentTableReg">alcaftadine solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0023-4290</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>alcaftadine</strong> (alcaftadine) </td>
<td class="formItem">alcaftadine</td>
<td class="formItem">2.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0023-4290-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0023-4290-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">3 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022134</td>
<td class="formItem">11/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Allergan, Inc.
							(144796497)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Allergan Sales, LLC</td>
<td class="formItem"></td>
<td class="formItem">362898611</td>
<td class="formItem">MANUFACTURE(0023-4290)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6e8def28-11dc-4e8d-9e0f-6f869a0f68da</div>
<div>Set id: 17d37e8d-7825-424b-b6ca-0a85d0bf4694</div>
<div>Version: 8</div>
<div>Effective Time: 20150930</div>
</div>
</div> <div class="DistributorName">Allergan, Inc.</div></p>
</body></html>
